Search results for "Macular degeneration"

showing 10 items of 114 documents

Association of neovascular age-related macular degeneration with month and season of birth in Italy

2016

In order to investigate the influence of season and month of birth on the risk of neovascular age-related macular degeneration (n-AMD) in Italy, we evaluated the month birth and sex of all patients, recorded in the anti-vascular endothelial growth factor (VEGF) monitoring registry of the Italian Medicines Agency, born between 1925-1944, who received intravitreal anti-VEGF injections for n-AMD between January 1, 2013 and July 29, 2015. The numbers of all births in Italy in the same years, extracted from the Italian National Institute of Statistics, were used to calculate the expected number of n-AMD cases. Overall, 45,845 patients (19,207 men, 26,638 women) received intravitreal anti-VEGF fo…

MaleVascular Endothelial Growth Factor AAginggenetic structuresMonth of birthVEGF receptorsneovascular AMDAngiogenesis InhibitorsAptamersMacular Degeneration0302 clinical medicineSeason of birthReceptors80 and overMedicineRegistriesAged 80 and overNeovascularization PathologicbiologyVascular Endothelial Growth FactorIncidenceIncidence (epidemiology)Aptamers NucleotideBevacizumabTreatment OutcomeItalyanti-VEGFFemaleSeasonsNucleotideNeovascular age-related macular degenerationResearch Papermedicine.drugAnti-VEGF; Month of birth; Neovascular age-related macular degeneration; Neovascular AMD; Season of birth; Aged; Aged 80 and over; Angiogenesis Inhibitors; Aptamers Nucleotide; Bevacizumab; Female; Humans; Incidence; Italy; Macular Degeneration; Male; Neovascularization Pathologic; Ranibizumab; Receptors Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Registries; Treatment Outcome; Vascular Endothelial Growth Factor A; Seasons; Aging; Cell BiologySeason of birthBevacizumabRecombinant Fusion ProteinsNeovascular AMDneovascular age-related macular degeneration03 medical and health sciencesRanibizumabAge relatedHumansNeovascularizationAgedPathologicseason of birthbusiness.industrymonth of birthAnti-VEGFCell BiologyMacular degenerationmedicine.diseaseeye diseasesanti-VEGF; month of birth; neovascular AMD; neovascular age-related macular degeneration; season of birthReceptors Vascular Endothelial Growth Factor030221 ophthalmology & optometrybiology.proteinsense organsRanibizumabbusinessMonth of birth030217 neurology & neurosurgeryDemographyAging
researchProduct

Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis).

2009

Purpose This prospective study examines the changes in short-term intraocular pressure (IOP) in patients with wet age-related macular degeneration (AMD) receiving intravitreal injections of 0.05 mL ranibizumab (Lucentis®) in a supine position. Methods A total of 45 eyes (45 patients, 16 M, 29 F, mean age: 78 y) received intravitreal ranibizumab injections for treatment of wet AMD (0.05 mL = 0.5 mg). The IOP was measured by Schiötz tonometry immediately preoperatively and postoperatively, and also after 3 and 10 minutes in a supine position. No history of glaucoma was present. Results The mean preoperative IOP was 22.4±5.5 mmHg in supine position. Immediately after the injection, IOP increas…

MaleVascular Endothelial Growth Factor AIntraocular pressuremedicine.medical_specialtySupine positiongenetic structuresAngiogenesis InhibitorsAntibodies Monoclonal HumanizedInjections03 medical and health sciencesTonometry Ocular0302 clinical medicineOphthalmologyRanibizumabWet age-related macular degenerationmedicineSupine PositionHumansIn patientProspective StudiesProspective cohort studyIntraocular PressureAgedAged 80 and overbusiness.industryAntibodies MonoclonalGeneral MedicineMacular degenerationMiddle Agedmedicine.diseaseeye diseasesVitreous BodyOphthalmology030221 ophthalmology & optometryWet Macular DegenerationFemalesense organsRanibizumabbusiness030217 neurology & neurosurgerymedicine.drugEuropean journal of ophthalmology
researchProduct

Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southe…

2022

Describe drug utilisation and clinical outcomes of intravitreal anti-VEGF drug and dexamethasone use in the real-world setting in Southern Italy using data from multi-centre study of retinal disease. Clinical data of retinal disease patients treated with anti-VEGF drugs and dexamethasone implant in 6 out-patient ophthalmology centres from Southern Italy were collected by means of an electronic case report form. Patients receiving at least one intravitreal injection/implant of the study drugs were followed for up to two years and described in terms of demographics and clinical characteristics. Drug utilisation patterns were described. A sign-rank test was used to compare clinical data on vi…

MaleVascular Endothelial Growth Factor Agenetic structuresPharmacology &ltPHARMACOLOGY diabetic macular edema &ltbiostatisticsAngiogenesis InhibitorsDexamethasoneMacular DegenerationCATARACTRetinal DiseasesRanibizumabRetinal Vein OcclusionHumansProspective StudiesRETINAAgedAged 80 and overPharmacologySettore MED/30 - Malattie Apparato Visivopathologic myopiaGeneral MedicineMiddle AgedBevacizumabOphthalmologyLENSRETINA epidemiology / biostatistics pathologic myopia retina - medical therapies &ltIntravitreal InjectionsPharmacology diabetic macular edema RETINA epidemiology biostatisticsLENSCATARACTpathologic myopiaFemaleepidemiologydiabetic macular edemaEuropean Journal of Ophthalmology
researchProduct

INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retin…

2016

To report the long-term anatomical and functional outcomes of patients with choroidal neovascularization secondary to age-related macular degeneration treated with intravitreal bevacizumab (IVB).Retrospective case series. Patients diagnosed with subfoveal choroidal neovascularization secondary to age-related macular degeneration that were treated with at least 1 intravitreal injection of 1.25 mg of IVB and had a minimum follow-up of 60 months. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits.Two hundred and forty-seven consecutive patients (292 eyes) were included. The mean number …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabVisual AcuityAngiogenesis InhibitorsOphthalmoscopy03 medical and health sciencesMacular Degeneration0302 clinical medicineOphthalmologyGeographic AtrophymedicineHumans030212 general & internal medicineFluorescein AngiographyAfliberceptAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryGeneral MedicineMacular degenerationMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesChoroidal NeovascularizationBevacizumabOphthalmoscopyOphthalmologyChoroidal neovascularizationTreatment OutcomeIntravitreal Injections030221 ophthalmology & optometryFemalesense organsmedicine.symptomRanibizumabbusinessTomography Optical Coherencemedicine.drugRetina (Philadelphia, Pa.)
researchProduct

Best-corrected visual acuity and retinal thickness are associated with improved cortical visual processing in treated wet AMD patients

2015

Purpose In response to anti-VEGF treatment for wet AMD retinal anatomy and visual acuity is often remedied. In our previous study, we showed that visual evoked potentials (VEP) improve following successful anti-VEGF treatment. The aim of this study was to investigate, how visual acuity and retinal thickness changes are reflected in VEP parameters. Moreover, we wanted to assess the feasibility of VEP as a novel monitoring tool for wet AMD patients. Methods A total of 16 patients and six control subjects were enrolled in this study. Patients received three bevacizumab intravitreal injections. At the beginning of the study and four to 6 weeks after the last injection, the best-corrected visual…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresexudative age-related macular degenerationvisual acuityAngiogenesis InhibitorsVisual systemRetinaVisual processingchemistry.chemical_compoundOphthalmologyMedicineHumansVisual PathwaysProspective Studiesage-related eye diseasesProspective cohort studyAgedVisual CortexBest corrected visual acuityAged 80 and overRetinaoptical coherence tomographybusiness.industryRetinalta3141General MedicineOrgan Sizeeye diseasesta3125BevacizumabOphthalmologymedicine.anatomical_structureVisual cortexchemistryIntravitreal InjectionsWet Macular DegenerationOptometryEvoked Potentials VisualFemalesense organsmedicine.symptomvisual evoked potentialbusinessTomography Optical CoherenceActa Ophthalmologica
researchProduct

Endophthalmitis after intravitreal injections: incidence, presentation, management, and visual outcome

2015

Purpose To report the incidence and characteristics of endophthalmitis after intravitreal injections of anti–vascular endothelial growth factor agents or corticosteroids and to describe the clinical and bacteriologic characteristics, management, and outcome of these eyes with acute endophthalmitis in France. Design Retrospective, nationwide multicenter case series. Methods From January 2, 2008 to June 30, 2013, a total of 316 576 intravitreal injections from 25 French ophthalmic centers were included. For each center, the number of intravitreal injections was determined using billing codes and the injection protocol was recorded. A registry and hospital records were reviewed to identify pat…

MaleVisual acuityfactor agentsVisual AcuityAngiogenesis InhibitorsEye Infections BacterialEndophthalmitisAntisepticRisk Factorscausative organismsrisk-factorsAged 80 and overEndophthalmitis[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyIncidence (epidemiology)IncidenceMiddle AgedAnti-Bacterial Agents[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansIntravitreal InjectionsFemaleFrancePresentation (obstetrics)medicine.symptommetaanalysisAdultmedicine.medical_specialtymacular degenerationmedicine.drug_classRetinal DiseasesmedicineHumansranibizumab[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansGlucocorticoidsAgedRetrospective Studiesocular surfaceBacteriabusiness.industryRetrospective cohort studyantibiotic-prophylaxisEye infectionmedicine.diseaseConfidence intervalSurgeryVitreous BodyOphthalmologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyoperating-roomendothelial growth-factor
researchProduct

The Effect of Central Vision Loss on Perception of Mutual Gaze

2014

People with central vision loss (CVL) often report difficulties with social interactions and reduced social functioning.1, 2 A limited access to the nonverbal visual cues inherent to effective communication can be a disadvantage in social interactions. Wang and Boerner3 reported that for people with vision impairment, difficulty in social situations was due either to the individual’s own lack of ability to perceive visual cues or other people’s lack of understanding. The facial region has been noted as an important source of nonverbal visual information relevant to social situations.4 Prior studies of individuals with CVL due to age-related macular degeneration have focused primarily on dif…

MaleVisual perceptionmedia_common.quotation_subjectPopulationVision LowFixation OcularArticleMacular DegenerationNonverbal communicationSurveys and QuestionnairesPerceptionSaccadesHumansFunctional abilityScotomaeducationSensory cueAgedmedia_commoneducation.field_of_studyMiddle AgedGazeOphthalmologyFixation (visual)Visual PerceptionFemaleVisual FieldsPsychologySocial psychologyOptometryOptometry and Vision Science
researchProduct

Serum vitamin E levels negatively correlate with severity of age-related macular degeneration.

1999

Age-related macular degeneration (AMD) pathogenesis has been related to UV radiation and other factors that may promote increased oxidative damage to the retina. Patients with different AMD grading (n = 25) were compared with an age-matched group of AMD-free subjects (n = 15), both groups older than 60 years. A modification of the AMD grading system is proposed that allows patient grading and not single eye grading. AMD patients showed statistically significant lower serum levels of vitamin E and Zn than AMD-free subjects. Moreover, a negative correlation (Spearman's correlation coefficient r = -0.815, P < 0.001) could be established between AMD grading of both the patients' eyes and serum …

Malemedicine.medical_specialtyAgingAntioxidantgenetic structuresmedicine.medical_treatmentmedicine.disease_causeGastroenterologyPathogenesisMacular DegenerationInternal medicineHyperlipidemiamedicineHumansVitamin EAgedbusiness.industryVitamin EMacular degenerationmedicine.diseaseeye diseasesSurgeryAgeingFemalesense organsbusinessOxidative stressDevelopmental BiologySerum vitamin eMechanisms of ageing and development
researchProduct

PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH RETINAL PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR D…

2007

Abstract PURPOSE: To assess the effectiveness of photodynamic therapy (PDT) with verteporfin for choroidal neovascularization (CNV) associated with retinal pigment epithelium detachment (PED) in age-related macular degeneration. METHODS: Thirty eyes of 26 patients with CNV and PED were treated with PDT. The eyes were divided in two groups based on CNV location in relation to PED; group 1 included 13 eyes with CNV within PED, and group 2 included 17 eyes with CNV at the edge of PED. The median follow-up was 16 months. RESULTS: Patients received a mean +/- SD of 2.83 +/- 1.26 treatments (range, 1-6 treatments). In the whole cohort, the mean preoperative visual acuity changed from 20/144 (0.86…

Malemedicine.medical_specialtyPorphyrinsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityPhotodynamic therapyMacular DegenerationAge relatedOphthalmologymedicineHumansProspective StudiesFluorescein AngiographyPigment Epithelium of EyeAgedAged 80 and overPhotosensitizing AgentsRetinal pigment epitheliumSettore MED/30 - Malattie Apparato Visivobusiness.industryRetinal DetachmentVerteporfinGeneral MedicineMiddle AgedMacular degenerationmedicine.diseaseVerteporfinChoroidal Neovascularizationeye diseasesOphthalmologyTreatment Outcomemedicine.anatomical_structureChoroidal neovascularizationPhotochemotherapyFemaleRetinal pigment epithelial detachmentsense organsPhotodynamic therapy choroidal neovascularization age-related macular degenerationmedicine.symptombusinessFollow-Up Studiesmedicine.drugRetina
researchProduct

Clinical Outcome and Subjective Quality of Life after Photodynamic Therapy in Patients with Age-Related Macular Degeneration

2005

PURPOSE. Whereas the efficacy of photodynamic therapy (PDT) in preventing the progression of age-related macular degeneration (ARMD) is established, its effect on quality of life is under discussion. METHODS. All patientswho underwent PDT during 2000 and 2001 at the University Eye Hospital of Mainz were interviewed using a standardized 82-item questionnaire on quality of life and patient satisfaction in ophthalmologic patients. Information was assessed in terms of 82 questions; global scores ranging from 1.0 (optimum self-estimated quality of life) to 4.0 (worst) were derived. Cataract patients' scores were used to characterize the ARMD patients' subjective outcome; the latter were then rel…

Malemedicine.medical_specialtyPorphyrinsVisual acuitymedicine.medical_treatmentVisual AcuityPsychological interventionPhotodynamic therapyLogistic regressionMacular Degeneration03 medical and health sciences0302 clinical medicinePatient satisfactionQuality of lifeSurveys and QuestionnairesInternal medicineActivities of Daily LivingmedicineHumansIn patientAgedRetrospective StudiesAged 80 and overPhotosensitizing Agentsbusiness.industryVerteporfinGeneral MedicineMacular degenerationmedicine.diseaseChoroidal Neovascularizationeye diseasesOphthalmologyCross-Sectional StudiesTreatment OutcomePhotochemotherapyPatient SatisfactionQuality of Life030221 ophthalmology & optometryPhysical therapyFemalemedicine.symptombusiness030217 neurology & neurosurgeryEuropean Journal of Ophthalmology
researchProduct